COL4A3 Degradation Predicts Anti-IgE Treatment Response in Severe Asthma

mehr
Titel COL4A3 Degradation Predicts Anti-IgE Treatment Response in Severe Asthma
Medien American Journal of Respiratory and Critical Care Medicine
Verfasser M Weckmann, T Bahmer, J Sand, S Ronnow, D Leeming, M Karsdal, L Lunding, M Wegmann, B Oliver, G Ulrich-Merzenich, U Juergens, U Zissler, M Jonker, I Konig, G Hansen, E von Mutius, O Fuchs, A Dittrich, B Schaub, C Happle, K Rabe, M Berge, J Burgess, M Kopp, Prof. Dr. Ulrich Zißler
Veröffentlichungsdatum 2020
Zitation Weckmann, M; Bahmer, T; Sand, J; Ronnow, S; Leeming, D; Karsdal, M; Lunding, L; Wegmann, M; Oliver, B; Ulrich-Merzenich, G; Juergens, U; Zissler, U; Jonker, M; Konig, I; Hansen, G; von Mutius, E; Fuchs, O; Dittrich, A; Schaub, B; Happle, C; Rabe, K; Berge, M; Burgess, J; Kopp, M; Zißler, Ulrich (2020): COL4A3 Degradation Predicts Anti-IgE Treatment Response in Severe Asthma. American Journal of Respiratory and Critical Care Medicine. DOI: 10.1164/AJRCCM-CONFERENCE.2020.201.1_MEETINGABSTRACTS.A5634